Research Paper Volume 15, Issue 20 pp 11588—11610

Immunobiological signatures and the emerging role of SPP1 in predicting tumor heterogeneity, malignancy, and clinical outcomes in stomach adenocarcinoma

class="figure-viewer-img"

Figure 6. Prognostic validation of risk signature. (AC) Kaplan–Meier survival analysis with p-value < 0.05 indicating that the established risk signature can identify high- and low-risk groups. (DF) Scatter plots showing the relationship between risk score and survival time. (GI) ROC curve to predict the accuracy of the patient's one-year, three-year, and five-year survival rate.